Cargando…
Advances in Cardiovascular Biomarker Discovery
Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and its pathological complications pose a major risk for the development of other cardiovascular diseases, including heart failure and stroke. Identifying novel and early stage biomarkers of hypertension...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759775/ https://www.ncbi.nlm.nih.gov/pubmed/33265898 http://dx.doi.org/10.3390/biomedicines8120552 |
_version_ | 1783627176324628480 |
---|---|
author | Ghantous, Crystal M. Kamareddine, Layla Farhat, Rima Zouein, Fouad A. Mondello, Stefania Kobeissy, Firas Zeidan, Asad |
author_facet | Ghantous, Crystal M. Kamareddine, Layla Farhat, Rima Zouein, Fouad A. Mondello, Stefania Kobeissy, Firas Zeidan, Asad |
author_sort | Ghantous, Crystal M. |
collection | PubMed |
description | Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and its pathological complications pose a major risk for the development of other cardiovascular diseases, including heart failure and stroke. Identifying novel and early stage biomarkers of hypertension and other cardiovascular diseases is of paramount importance in predicting and preventing the major morbidity and mortality associated with these diseases. Biomarkers of such diseases or predisposition to their development are identified by changes in a specific indicator’s expression between healthy individuals and patients. These include changes in protein and microRNA (miRNA) levels. Protein profiling using mass spectrometry and miRNA screening utilizing microarray and sequencing have facilitated the discovery of proteins and miRNA as biomarker candidates. In this review, we summarized some of the different, promising early stage protein and miRNA biomarker candidates as well as the currently used biomarkers for hypertension and other cardiovascular diseases. Although a number of promising markers have been identified, it is unlikely that a single biomarker will unambiguously aid in the classification of these diseases. A multi-marker panel-strategy appears useful and promising for classifying and refining risk stratification among patients with cardiovascular disease. |
format | Online Article Text |
id | pubmed-7759775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77597752020-12-26 Advances in Cardiovascular Biomarker Discovery Ghantous, Crystal M. Kamareddine, Layla Farhat, Rima Zouein, Fouad A. Mondello, Stefania Kobeissy, Firas Zeidan, Asad Biomedicines Review Cardiovascular diseases are the leading causes of mortality worldwide. Among them, hypertension and its pathological complications pose a major risk for the development of other cardiovascular diseases, including heart failure and stroke. Identifying novel and early stage biomarkers of hypertension and other cardiovascular diseases is of paramount importance in predicting and preventing the major morbidity and mortality associated with these diseases. Biomarkers of such diseases or predisposition to their development are identified by changes in a specific indicator’s expression between healthy individuals and patients. These include changes in protein and microRNA (miRNA) levels. Protein profiling using mass spectrometry and miRNA screening utilizing microarray and sequencing have facilitated the discovery of proteins and miRNA as biomarker candidates. In this review, we summarized some of the different, promising early stage protein and miRNA biomarker candidates as well as the currently used biomarkers for hypertension and other cardiovascular diseases. Although a number of promising markers have been identified, it is unlikely that a single biomarker will unambiguously aid in the classification of these diseases. A multi-marker panel-strategy appears useful and promising for classifying and refining risk stratification among patients with cardiovascular disease. MDPI 2020-11-30 /pmc/articles/PMC7759775/ /pubmed/33265898 http://dx.doi.org/10.3390/biomedicines8120552 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ghantous, Crystal M. Kamareddine, Layla Farhat, Rima Zouein, Fouad A. Mondello, Stefania Kobeissy, Firas Zeidan, Asad Advances in Cardiovascular Biomarker Discovery |
title | Advances in Cardiovascular Biomarker Discovery |
title_full | Advances in Cardiovascular Biomarker Discovery |
title_fullStr | Advances in Cardiovascular Biomarker Discovery |
title_full_unstemmed | Advances in Cardiovascular Biomarker Discovery |
title_short | Advances in Cardiovascular Biomarker Discovery |
title_sort | advances in cardiovascular biomarker discovery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759775/ https://www.ncbi.nlm.nih.gov/pubmed/33265898 http://dx.doi.org/10.3390/biomedicines8120552 |
work_keys_str_mv | AT ghantouscrystalm advancesincardiovascularbiomarkerdiscovery AT kamareddinelayla advancesincardiovascularbiomarkerdiscovery AT farhatrima advancesincardiovascularbiomarkerdiscovery AT zoueinfouada advancesincardiovascularbiomarkerdiscovery AT mondellostefania advancesincardiovascularbiomarkerdiscovery AT kobeissyfiras advancesincardiovascularbiomarkerdiscovery AT zeidanasad advancesincardiovascularbiomarkerdiscovery |